Applied DNA Sciences, Inc. (APDN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2000 |
| Open | 1.2100 |
| Bid | 1.2100 x 1000 |
| Ask | 1.2500 x 1300 |
| Day's Range | 1.2100 - 1.2999 |
| 52 Week Range | 0.9700 - 3.2000 |
| Volume | |
| Avg. Volume | 179,109 |
| Market Cap | 16.527M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings Date | Dec 12, 2023 - Dec 18, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APDN
Related Research
- Applied DNA Sciences, Inc.Daily – Vickers Top Buyers & Sellers for 08/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
ACCESSWIREApplied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA' or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine ("CUCVM") today announced the signing of a sponsored research agreement (the "Agreement") for a translational research study to accelerate the development and optimization of the Company's LineaDNA™-lipid nano particle (LNP)-based veterinary
- ACCESSWIRE
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs.
- ACCESSWIRE
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the general availability of Linea™ IVT platform evaluation kits (the "Kit") and the first shipment of a Kit to an existing Linea™ IVT Template customer.
